February is National Sudden Cardiac Arrest Awareness Month—a time to strengthen public understanding of one of the most urgent and often misunderstood cardiovascular events. Supported by the Sudden Cardiac Arrest Foundation and aligned with the American Heart Association’s CPR initiatives, this observance carries a practical message: awareness saves lives, and preparation matters.
Sudden cardiac arrest claims more than 350,000 lives in the United States each year. It strikes across age groups, often without warning, and survival depends not just on medical care but on the people present in those first critical minutes. This month is an opportunity to learn—not only about what to do in an emergency, but about the underlying biology that can quietly precede cardiac events, and how measurable data can support more proactive conversations with healthcare providers.
What Is Sudden Cardiac Arrest?
Sudden cardiac arrest is not a single disease but a catastrophic electrical failure of the heart—a collapse of the coordinated rhythm that keeps blood moving. Understanding what it is, and what it is not, is the first step toward meaningful awareness.
How It Differs From a Heart Attack
These two events are frequently confused, and the distinction matters. A heart attack (myocardial infarction) is a circulation problem: a blocked artery cuts off blood supply to part of the heart muscle, causing damage over time. The person typically remains conscious and may describe chest pain, pressure, shortness of breath, or arm and jaw discomfort.
Sudden cardiac arrest is an electrical problem: the heart’s rhythm becomes fatally disrupted, causing the heart to stop pumping effectively. The person loses consciousness within seconds. They have no pulse. Without immediate intervention, brain damage begins within four to six minutes.
That said, these events are not unrelated. A heart attack can trigger sudden cardiac arrest by creating electrical instability in the damaged heart tissue. Understanding the upstream contributors to both is central to the awareness this month promotes.
The Electrical Failure Behind SCA
In the majority of SCA cases, the underlying arrhythmia is ventricular fibrillation (VF)—a chaotic, disorganized electrical pattern in which the heart quivers rather than contracts. Ventricular tachycardia (VT) that degenerates into VF is another common pathway. In either case, cardiac output collapses, and the body’s organs—including the brain—are rapidly deprived of oxygenated blood.
Some SCA events occur in structurally normal hearts due to inherited electrical conditions (discussed below). But the majority are linked to underlying structural or ischemic heart disease, which is why biomarker awareness has a meaningful role to play in this conversation.
Why Immediate Action Saves Lives
When cardiac arrest occurs, the clock starts immediately. What happens in the first few minutes—and who is nearby—determines whether a person survives.
The Role of CPR
Cardiopulmonary resuscitation (CPR) maintains a minimal level of blood circulation to the brain and vital organs until a defibrillator can restore normal heart rhythm. Hands-Only CPR—two steps, as promoted by the American Heart Association: call 911, then push hard and fast in the center of the chest—can double or triple survival rates when started quickly.
Bystander CPR is one of the most powerful interventions available. Yet surveys consistently show that a significant portion of the public is either untrained or uncertain. This Awareness Month is an appropriate moment to take or retake a CPR certification course, and to encourage family members and colleagues to do the same.
AED Access and Survival Rates
An automated external defibrillator (AED) delivers a controlled electrical shock to the heart with the goal of restoring a normal rhythm. AEDs are designed for public use—they provide verbal instructions and are safe for untrained bystanders to operate. When used within three to five minutes of collapse, AEDs can increase survival from cardiac arrest by more than 50%.
AEDs are increasingly available in schools, airports, gyms, and public spaces—but coverage remains uneven, particularly in rural and lower-income communities. Advocacy for expanded AED access is a concrete action anyone can support.
Who May Be at Higher Risk?
Sudden cardiac arrest does not occur randomly. In most cases, there are underlying conditions—some known, some silent—that elevate risk. Understanding these pathways is central to biomarker-informed cardiac awareness.
Coronary Artery Disease
Coronary artery disease (CAD) is the most common substrate for sudden cardiac arrest in adults over 35. When atherosclerotic plaques—deposits of lipids, inflammatory cells, and fibrous tissue—build up in the coronary arteries, they narrow blood supply to the heart muscle and create vulnerable sites for rupture. A plaque rupture triggers rapid clot formation, which can occlude an artery and set off the cascade that leads to heart attack and, in some cases, arrest.
CAD develops over years, often without symptoms. High blood pressure, elevated LDL cholesterol, diabetes, smoking, and chronic inflammation are among the most significant modifiable risk factors—which is why lipid and inflammation markers carry relevance as part of proactive cardiovascular monitoring.
Cardiomyopathies and Structural Abnormalities
Hypertrophic cardiomyopathy (HOCM) is the most common cause of sudden cardiac death in young athletes. In this condition, the heart muscle—particularly the left ventricle—is abnormally thickened, making it prone to dangerous arrhythmias during intense exercise. Many individuals with HOCM are asymptomatic until a cardiac event occurs, which is why screening in competitive athletes has become a subject of ongoing clinical discussion.
Other structural conditions, including dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy (ARVC), also carry elevated SCA risk. Echocardiography, which measures ejection fraction (EF) and cardiac dimensions, is the primary tool for identifying structural abnormalities. An EF consistently below 35% is associated with significantly elevated sudden death risk and is one threshold that may prompt consideration of an implantable defibrillator.
Channelopathies and Genetic Risk
Some individuals with structurally normal hearts carry inherited mutations that affect the electrical channels governing cardiac rhythm. Long QT syndrome (LQTS), Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT) are among the most recognized inherited channelopathies.
These conditions can be identified through ECG findings (such as a prolonged QT interval) and genetic panels. Variants in genes such as KCNQ1 and RYR2 have been associated with these syndromes. For individuals with a family history of unexplained sudden death, particularly in young relatives, specialist consultation and genetic evaluation may be appropriate—a conversation to have with a cardiologist or genetic counselor.
Warning Symptoms Before Collapse
Sudden cardiac arrest is not always entirely without warning. In retrospect, many survivors or their families recall preceding symptoms: unexplained syncope (fainting), near-syncope, sustained palpitations, exertional chest pain, or unusual shortness of breath.
These symptoms warrant prompt medical evaluation—not reassurance or delay. If you or someone you know experiences any of these, particularly in association with exercise, it is important to seek care rather than wait. Emergency symptoms—chest pain, collapse, loss of pulse—always require calling 911 immediately.
Key Biomarkers Linked to Cardiac Risk
Blood biomarkers cannot predict sudden cardiac arrest. That point is foundational and bears being said clearly. What they can do is reflect biological activity—inflammation, myocardial stress, coronary disease risk, electrolyte balance—that is associated with the underlying conditions that raise SCA risk. As supportive, contextual data, they have a meaningful role in proactive health monitoring.
High-Sensitivity Troponin and Silent Ischemia
Troponin is a protein released into the bloodstream when heart muscle cells are injured or under significant stress. In emergency medicine, it is a primary marker used to identify acute myocardial infarction. High-sensitivity troponin (hs-Tn) testing can detect very low levels of myocardial injury—including subclinical damage that may not cause obvious symptoms.
Chronically elevated troponin, even at low levels, has been associated in research settings with higher cardiovascular risk. It may reflect ongoing ischemia, cardiac strain, or early myocardial disease. It is important to note that any troponin elevation requires medical evaluation—it is not a number to self-interpret or dismiss. In acute symptom settings, elevated troponin is a medical emergency. In wellness monitoring contexts, even modestly elevated hs-Tn warrants discussion with a healthcare provider.
Potassium and Magnesium in Arrhythmia Risk
Electrolytes—particularly potassium and magnesium—play a direct role in the electrical stability of the heart. These minerals regulate ion channel activity that governs the timing and coordination of cardiac contractions. When potassium or magnesium levels fall outside normal ranges, the risk of arrhythmia increases.
Hypokalemia (low potassium) and hypomagnesemia (low magnesium) are associated with ventricular arrhythmias and are particularly relevant in individuals taking diuretics, those with gastrointestinal losses, or those with dietary insufficiency. An electrolyte panel is one of the most accessible and informative blood tests available—and for individuals with conditions or medications that affect electrolyte balance, periodic monitoring can provide reassuring or actionable data.
NT-proBNP and Cardiomyopathy
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is released by the heart’s ventricles in response to increased wall stress and volume overload. It is a sensitive marker of cardiac strain and is used clinically to support the diagnosis and monitoring of heart failure.
In the context of SCA awareness, NT-proBNP is relevant because cardiomyopathies—which carry elevated sudden death risk—often produce elevated natriuretic peptide levels as the heart compensates for structural changes. While NT-proBNP does not diagnose cardiomyopathy, persistently elevated levels may prompt further evaluation, including echocardiography. For individuals with risk factors for structural heart disease, it adds a useful layer of context to a biomarker baseline.
Lipid Panel and Coronary Disease Risk
A standard lipid panel measures total cholesterol, LDL (low-density lipoprotein), HDL (high-density lipoprotein), and triglycerides. LDL in particular is a primary driver of atherosclerosis—the plaque-building process that underlies the vast majority of sudden cardiac arrests in adults.
Guidelines from major cardiovascular organizations support regular lipid screening beginning in early adulthood, with frequency increasing based on risk factors. Knowing your LDL trajectory over time, rather than a single measurement, provides more useful information about coronary disease risk. For individuals with elevated LDL, hypertension, diabetes, or family history of early cardiovascular disease, the lipid panel is a foundational monitoring tool.
CRP and Plaque Inflammation
C-reactive protein (CRP)—specifically high-sensitivity CRP (hs-CRP)—reflects systemic inflammatory activity. In the cardiovascular context, elevated CRP is associated with a higher likelihood of vulnerable, inflamed plaques that are more prone to rupture. The landmark JUPITER trial demonstrated that individuals with elevated hs-CRP but normal LDL cholesterol benefited from statin therapy in terms of cardiovascular event reduction—illustrating how CRP adds risk information beyond the lipid panel alone.
CRP is not a cardiac-specific marker; it rises with any inflammatory process. But in the context of other cardiovascular risk factors, elevated hs-CRP can contribute meaningfully to a more complete risk picture. Levels above 3 mg/L are generally considered to reflect higher inflammatory burden, though interpretation always depends on the broader clinical context.
What Lab Testing Can—and Cannot—Tell You
Understanding the appropriate role of biomarkers—as complementary data, not diagnostic tools—is essential to using them wisely.
Blood Tests vs. ECG and Imaging
An electrocardiogram (ECG) measures the heart’s electrical activity in real time and can identify QT prolongation, left ventricular hypertrophy (LVH), conduction abnormalities, and patterns associated with inherited channelopathies. It is a primary screening tool and a necessary component of cardiac evaluation—something no blood test can replicate.
Echocardiography provides structural information: heart chamber dimensions, wall thickness, valvular function, and ejection fraction. It is the primary tool for identifying hypertrophic cardiomyopathy and monitoring cardiomyopathy progression. Again, no lab marker substitutes for this.
Blood biomarkers occupy a different and complementary lane. They can reflect the metabolic, inflammatory, and ischemic environment in which cardiac events develop—providing context that ECG and imaging alone do not always capture. Used together, they build a more complete picture.
When Specialist Evaluation Is Required
Certain findings—or family histories—indicate that self-directed biomarker monitoring is not sufficient and specialist consultation is essential. These include a family history of sudden cardiac death, especially in relatives under 50; a personal history of unexplained syncope or sustained palpitations; ECG findings such as significant QT prolongation; or any troponin elevation.
For young athletes, many sports medicine physicians and cardiologists recommend a pre-participation evaluation that includes history, physical examination, and ECG. The appropriate scope of that evaluation—and whether echocardiography or genetic testing is warranted—is a clinical conversation, not a self-directed decision.
Who May Benefit From Preventive Screening
Proactive biomarker monitoring is not universally indicated, but for specific groups, it provides a rational and meaningful framework for ongoing cardiac awareness.
Athletes and Youth Sports Participants
Athletes represent a population in which sudden cardiac arrest is particularly visible and particularly devastating. The sudden death of a competitive athlete, often young and seemingly in peak health, carries enormous emotional impact—and raises important questions about screening.
For athletes with symptoms (palpitations, chest pain, exertional presyncope) or a family history of sudden death or inherited cardiac conditions, evaluation is clearly warranted. For others, the appropriate scope of screening remains an evolving clinical and policy question. What is clear is that parents of student athletes, coaches, and athletic programs benefit from awareness of warning signs, access to AEDs, and CPR training.
For adult recreational athletes, particularly those who have significantly increased training intensity in midlife, biomarker monitoring—including lipid panel, hs-CRP, and electrolytes—alongside regular check-ins with a primary care provider, represents a rational approach to cardiac health maintenance.
Adults 45+ With Risk Factors
Adults aged 45 and older who carry cardiovascular risk factors—hypertension, hyperlipidemia, diabetes, smoking history, obesity, or family history of early heart disease—represent the group in whom coronary artery disease risk is most concentrated. For this population, regular biomarker monitoring provides an ongoing measure of modifiable risk factors and their trajectory over time.
Tracking LDL cholesterol, hs-CRP, and NT-proBNP alongside blood pressure and fasting glucose creates a comprehensive metabolic and inflammatory picture. Any persistent abnormality in these markers is an invitation to a more detailed clinical conversation—not a cause for alarm, but a signal worth exploring.
Families With History of Sudden Death
Perhaps the most high-stakes population for proactive cardiac awareness is families who have experienced unexplained sudden death in a first-degree relative, particularly at a young age. In these families, inherited cardiac conditions—including channelopathies and cardiomyopathies—may be present across generations.
For family members in this situation, the appropriate first step is specialist referral, not consumer testing. A cardiologist or cardiac geneticist can guide the evaluation, including ECG, echocardiography, and where appropriate, genetic panels. Biomarker monitoring may play a supplementary role in ongoing care, but it is not a starting point for this level of risk.
Taking Ownership of Cardiac Health Data
Awareness is a beginning, not an endpoint. For those who want to move from concern to action, building a personal cardiac health baseline is a concrete and empowering step.
Building a Cardiac Biomarker Baseline
A baseline is most useful when established before any specific concern arises—while values are presumably normal and trends are yet to develop. For adults in the 35–65 range, particularly those with any cardiovascular risk factors, a baseline that includes a lipid panel, hs-CRP, NT-proBNP, and an electrolyte panel provides a meaningful starting point.
Direct-to-consumer (DTC) lab testing makes many of these panels accessible without waiting for a provider-ordered workup. High-sensitivity troponin is also available through some DTC platforms—though any elevated result should prompt prompt medical discussion. The goal of baseline testing is to establish a personal reference point, not to seek out disease.
Monitoring Electrolytes and Inflammation
For individuals on diuretics, ACE inhibitors, or medications known to affect electrolyte levels, periodic potassium and magnesium monitoring provides straightforward reassurance—or flags a value worth addressing. Similarly, for those who have made lifestyle changes aimed at reducing inflammation (dietary changes, smoking cessation, increased physical activity), tracking hs-CRP over time can provide tangible feedback on whether those changes are reflected in systemic inflammatory activity.
Biomarker tracking is most useful when interpreted as a trend rather than a single point. A single elevated CRP is non-specific. A CRP that has declined consistently over six months following a dietary intervention tells a more meaningful story.
Preparing for Informed Cardiologist Conversations
One of the most practical applications of biomarker monitoring is as preparation for clinical conversations. Walking into a cardiology appointment with a documented trend of your LDL, CRP, and NT-proBNP values—alongside questions about their significance—positions you as an engaged partner in your care.
Healthcare providers respond well to patients who bring data and ask specific questions. “My NT-proBNP has been at the high end of normal for the past year—given my family history, is that worth investigating further?” is a far more productive starting point than a general conversation about feeling unwell. Data creates direction.
Closing: Preparedness Begins With Awareness
Sudden cardiac arrest is frightening in part because it can seem to come from nowhere. But for most people, it does not arise in a vacuum. It develops from conditions—coronary disease, cardiomyopathy, electrolyte imbalance, systemic inflammation—that build over time, often quietly, and that are increasingly measurable.
This Awareness Month, the most important things anyone can do remain: learn CPR, know where the nearest AED is, and understand the warning symptoms that warrant immediate action. These are the interventions that directly save lives in the moment.
But alongside those essentials, there is growing value in understanding your own cardiac risk profile—through biomarkers, regular provider conversations, and honest attention to family history. Lab data does not prevent cardiac arrest. But it can inform the conversations that lead to earlier evaluation, better risk management, and greater peace of mind.
Preparedness is not a single action. It is an ongoing posture—one that combines emergency readiness with proactive health awareness. Both matter. Both are within reach.
This article is for educational purposes only. It does not constitute medical advice and is not a substitute for evaluation by a licensed healthcare professional. Biomarkers discussed here provide supportive health context—they do not diagnose or predict cardiac events. Always consult a qualified provider before making decisions based on lab results. If you or someone near you experiences chest pain, collapse, or loss of pulse, call 911 immediately.
